Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?

[Guest guest]

Vaccine. 2010 Jul 15. [Epub ahead of print]

Are young injection drug users ready and willing to participate in preventive

HCV vaccine trials?

Levy V, JL, Stein ES, son PJ, Lum PJ, Hahn JA, Page K.

San Mateo County Health Systems, San Mateo, CA, United States; Stanford

University, Division of Infectious Diseases, Stanford, CA, United States.

Abstract

Trials to evaluate the efficacy of preventive HCV vaccines will need

participation from high risk HCV seronegative injection drug users (IDUs). To

guide trial planning, we assessed willingness of young IDU in San Francisco to

participate in HCV vaccine efficacy trials and evaluate knowledge of vaccine

trial concepts: placebo, randomization and blinding. During 2006 and 2007, a

total of 67 participants completed the survey. A substantial proportion (88%)

would definitely (44%) or probably (44%) be willing to participate in a

randomized trial, but knowledge of vaccine trial concepts was low. Reported

willingness to participate in an HCV vaccine trial decreased with increasing

trial duration, with 67% of participants surveyed willing to participate in a

trial of 1 year duration compared to 43% of participants willing to participate

in a trial of 4 years duration. Willingness to enroll in HCV vaccine trials was

higher in young IDU than reported by most at-risk populations in HIV vaccine

trials. Educational strategies will be needed to ensure understanding of key

concepts prior to implementing HCV vaccine trials. . Published

by Elsevier Ltd.

PMID: 20638453

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2

[Guest guest]

Vaccine. 2010 Jul 15. [Epub ahead of print]

Are young injection drug users ready and willing to participate in preventive

HCV vaccine trials?

Levy V, JL, Stein ES, son PJ, Lum PJ, Hahn JA, Page K.

San Mateo County Health Systems, San Mateo, CA, United States; Stanford

University, Division of Infectious Diseases, Stanford, CA, United States.

Abstract

Trials to evaluate the efficacy of preventive HCV vaccines will need

participation from high risk HCV seronegative injection drug users (IDUs). To

guide trial planning, we assessed willingness of young IDU in San Francisco to

participate in HCV vaccine efficacy trials and evaluate knowledge of vaccine

trial concepts: placebo, randomization and blinding. During 2006 and 2007, a

total of 67 participants completed the survey. A substantial proportion (88%)

would definitely (44%) or probably (44%) be willing to participate in a

randomized trial, but knowledge of vaccine trial concepts was low. Reported

willingness to participate in an HCV vaccine trial decreased with increasing

trial duration, with 67% of participants surveyed willing to participate in a

trial of 1 year duration compared to 43% of participants willing to participate

in a trial of 4 years duration. Willingness to enroll in HCV vaccine trials was

higher in young IDU than reported by most at-risk populations in HIV vaccine

trials. Educational strategies will be needed to ensure understanding of key

concepts prior to implementing HCV vaccine trials. . Published

by Elsevier Ltd.

PMID: 20638453

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2